Paper Details

  1. Home
  2. Paper Details

Analysis of the Effects of the Bruton's tyrosine kinase (Btk) Inhibitor Ibrutinib on Monocyte Fcγ Receptor (FcγR) Function.

Author: ButcharJonathan P, ByrdJohn C, CampbellAmanda, CarsonWilliam E, ElavazhaganSaranya, FangHuiqing, FatehchandKavin, GautamShalini, MehtaPayal, MoXiaokui, ReaderBrenda F, RenLi, StiffAndrew, TridandapaniSusheela

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.

Overview

Ibrutinib, a Bruton's tyrosine kinase (Btk) inhibitor, does not affect monocyte FcγR-mediated phagocytosis but suppresses FcγR-mediated cytokine production. This effect of ibrutinib can be overcome by IFNγ priming. Combining ibrutinib with monoclonal antibody therapy could enhance chronic lymphocytic leukemia cell killing without affecting macrophage effector function.
Paper Details　
Original Abstract of the Article :
The irreversible Bruton's tyrosine kinase (Btk) inhibitor ibrutinib has shown efficacy against B-cell tumors such as chronic lymphocytic leukemia and B-cell non-Hodgkin lymphoma. Fcγ receptors (FcγR) on immune cells such as macrophages play an important role in tumor-specific antibody-mediated immun...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4742765/

データ提供：米国国立医学図書館（NLM）

Ibrutinib: Navigating the Complexities of Btk Inhibition and Immune Responses

Ibrutinib, a Bruton's tyrosine kinase (Btk) inhibitor, has emerged as a promising treatment for B-cell malignancies. This study explores the intricate interplay between ibrutinib's action on Btk and its impact on monocyte Fcγ receptor (FcγR) function, a crucial aspect of immune responses. The research delves into the mechanisms underlying ibrutinib's effects, analyzing its influence on phagocytosis and cytokine production.

Ibrutinib: A Selective Inhibitor with Potential Therapeutic Implications

The study demonstrates that ibrutinib, while effectively inhibiting Btk, has a selective effect on FcγR-mediated activities. It suppresses cytokine production without compromising phagocytosis, suggesting a potential for enhancing antibody-mediated immune responses while preserving essential immune functions.

Balancing Immunity and Cancer Treatment

This research highlights the complex interplay between cancer treatments and immune responses. Understanding the specific effects of medications like ibrutinib on immune cells is crucial for optimizing treatment strategies and minimizing potential side effects.

Dr.Camel's Conclusion

This study offers a glimpse into the intricate world of Btk inhibition and its implications for immune responses. Much like a camel carefully navigating a desert landscape, researchers are diligently exploring the potential of ibrutinib to effectively target B-cell malignancies while preserving crucial immune functions.

Date :
  1. Date Completed 2016-06-24
  2. Date Revised 2021-12-03
Further Info :

Pubmed ID

26627823

DOI: Digital Object Identifier

PMC4742765

Related Literature

Article Analysis
・Effects of ibrutinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.